Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Sleep Apnea

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Ischemic Heart Disease: Overview

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Event rates of patients with stable heart failure with reduced ejection fraction and newly diagnosed obstructive or central sleep apnoea.

European journal of heart failure·2026

Same author

Baroreflex activation therapy for resistant hypertension: promise present or passed?

Journal of hypertension·2026

Same author

Discordant ventilatory and efferent sympathetic responsiveness to peripheral and central chemoreflex stimulation in heart failure with reduced ejection fraction.

European journal of heart failure·2026

Same author

Reflex Neurogenic Vasoconstriction When Patients With Heart Failure Exercise: Are Females More Sympathetic Than Males?

JACC. Advances·2026

Same author

Win Ratio Analysis for Peak-Flow Adaptive Servoventilation in Treating Sleep Apnoea in Heart Failure With Reduced Ejection Fraction.

The Canadian journal of cardiology·2026

Same author

Comment on ERS/ESRS statement on adaptive servo-ventilation for treatment of central sleep apnoea.

The European respiratory journal·2026

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Obstructive sleep apnoea and its cardiovascular consequences.

T Douglas Bradley¹, John S Floras

¹Sleep Research Laboratory of the Toronto Rehabilitation Institute, Toronto, Canada.

Lancet (London, England)

|December 23, 2008

Summary

Obstructive sleep apnoea (OSA) significantly impacts cardiovascular health, increasing risks for conditions like hypertension and heart failure. Treating OSA may reduce these risks, but large trials are needed to confirm improved cardiovascular outcomes.

More Related Videos

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Related Experiment Videos

Last Updated: Jun 26, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

Area of Science:

Cardiology
Sleep Medicine
Internal Medicine

Background:

Obstructive sleep apnoea (OSA) involves repetitive breathing cessations during sleep.
These events lead to hypoxia, negative intrathoracic pressure, and arousals, stressing the cardiovascular system.
OSA is linked to increased risks of hypertension, coronary artery disease, heart failure, and stroke.

Purpose of the Study:

To review the cardiovascular implications of obstructive sleep apnoea.
To evaluate the potential benefits of treating OSA on cardiovascular health.
To identify the need for further large-scale clinical trials.

Main Methods:

Review of epidemiological studies on OSA and cardiovascular disease.
Analysis of data from randomized trials investigating continuous positive airway pressure (CPAP) treatment for OSA.
Synthesis of current evidence on the pathophysiological mechanisms linking OSA to cardiovascular events.

Main Results:

OSA triggers detrimental cardiovascular stimuli including hypoxia, sympathetic activation, and inflammation.
Treatment with CPAP has shown benefits such as reduced blood pressure and improved cardiac function in heart failure patients.
Epidemiological data strongly associate OSA with major cardiovascular diseases.

Conclusions:

Obstructive sleep apnoea is a significant risk factor for cardiovascular diseases.
Treatment of OSA, particularly with CPAP, shows promise in mitigating cardiovascular risk.
Further large-scale randomized trials are essential to definitively establish whether OSA treatment improves cardiovascular outcomes.